-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest data from Intranet, the sales scale of proprietary Chinese medicines in public hospitals in key cities in 2022H1 exceeded 15 billion yuan, and Beijing led the sales scale; Drugs for cardiovascular and cerebrovascular diseases are the first best-selling category, and dermatology drugs and blood replenishment drugs have increased by more than 15%.
Among the top 20 products, Golden Water Treasure tablets once again ranked first, and 12 products were exclusive varieties; Among the top 20 brands, Zuoli, Yangtze River, Beida Weixin.
.
.
5 brands have seen impressive growth
.
Cardiovascular and cerebrovascular diseases lead the way, with three major categories up more than 10%
Cardiovascular and cerebrovascular diseases lead the way, with three major categories up more than 10%According to the latest data from Intranet, due to the rebound of the domestic epidemic and the promotion of volume procurement, the sales scale of terminal proprietary Chinese medicines in public hospitals in key cities in the first half of 2022 exceeded 15 billion yuan, an increase of only 0.
3%
year-on-year.
Among them, the sales scale in the first quarter increased by 7.
05% over the same period last year, and in the second quarter, it fell by 5.
82%
year-on-year.
Sales of proprietary Chinese medicines in public hospitals in key cities (100 million yuan)
Source: Competition pattern of proprietary Chinese medicine terminals in public hospitals in key cities of Intranet
From the perspective of urban pattern, the sales scale of Beijing, Guangzhou and Chongqing ranked the top three, however, the sales scale of proprietary Chinese medicines in Beijing public hospitals exceeded 5 billion yuan, far ahead of other cities; Sales scale achieved positive growth in 7 cities, including Ningbo, Hangzhou, Chongqing, Wuhu, Nanjing, Qingdao and Jinan
.
Among the 13 categories of proprietary Chinese medicine treatment, cardiovascular and cerebrovascular diseases are the first best-selling category, with a market share of nearly 30%; The market share of drugs for tumor diseases, musculoskeletal system diseases and respiratory diseases exceeded 10%; The sales of three categories, including dermatology drugs, qi and blood replenishment drugs, and neurological disease drugs, performed well, with year-on-year increases of 16.
76%, 15.
65%, and 10.
30%
respectively.
2022H1 Pattern of proprietary Chinese medicines in public hospitals in key cities
Source: Competition pattern of proprietary Chinese medicine terminals in public hospitals in key cities of Intranet
Top 20 proprietary Chinese medicines are out! 12 exclusive proprietary Chinese medicines are eye-catching
Top 20 proprietary Chinese medicines are out! 12 exclusive proprietary Chinese medicines are eye-catchingAmong the TOP20 proprietary Chinese medicine products, Jinshuibao tablets once again ranked first, Bailing capsules and Suhuang cough capsules ranked second and third respectively; The sales scale of 16 products exceeded 100 million yuan, of which Jinshuibao tablets, Bailing capsules and Suhuang cough capsules all exceeded 200 million yuan
.
2022H1 TOP20 proprietary Chinese medicine products in public hospitals in key cities
Source: Competition pattern of proprietary Chinese medicine terminals in public hospitals in key cities of Intranet
The 20 products involve 8 treatment categories, among which, as many as 7 products are listed for cardiovascular and cerebrovascular diseases, 4 products are on the list for tumor diseases, and 3 products are on the list
for urinary system diseases.
The 12 products are exclusive proprietary Chinese medicines, including Suhuang cough capsules and Lanqin oral liquid from Yangtze River Pharmaceutical Group, Pediatric Qiaoqing Heat Granules from Jichuan Pharmaceutical, Tasly's compound salvia drop pills, Bailing capsules from Sino-American East China, Musk Baoxin Pills from Hutchison Pharmaceutical, and Xuezhikang capsules from Peking University Weixin
.
5 brands soared by more than 10%, Zuoli, Yangtze River, Beida Weixin.
.
.
.
.
Among the top 20 proprietary Chinese medicine brands, Jimin Credible Jinshuibao tablets ranked first, Bailing capsules from East China and the United States ranked second, Yangtze River Pharmaceutical Group's Suhuang cough capsules and Lanqin oral liquid ranked third and fourth, respectively, and Jichuan Pharmaceutical's Pediatric Qiaoqing Heat Granules ranked fifth
.
2022H1 TOP20 proprietary Chinese medicine brands in public hospitals in key cities
Source: Competition pattern of proprietary Chinese medicine terminals in public hospitals in key cities of Intranet
From the perspective of sales changes, 12 of the 20 brands achieved positive growth, and 5 brands soared by more than 10%, including Suhuang cough capsules from Yangtze River Pharmaceutical Group, Musk Baoxin Pills from Hutchison Pharmaceutical, Tongguan Vine Injection from Nanjing Shenghe Pharmaceutical, Xuezhikang capsules from Beida Weixin, and Wuling Capsules
from Zuoli Pharmaceutical.
Except for the clearance vine injection, the rest are exclusive varieties
.
Zuoli Pharmaceutical's Wuling capsules are made of a single ingredient Wuling mushroom powder, which has the effect of tonifying the kidneys and strengthening the brain, nourishing the heart and calming the mind, suitable for neurasthenic heart and kidney non-communication, and is a national medical insurance class A, national basic medicine, OTC class A variety
.
According to data from Intranet, the terminal sales scale of Wuling capsules in public hospitals in key cities has continued to rise in recent years, with a year-on-year increase of 13.
63% in 2021 and a 22.
55%
increase in 2022H1 compared with the same period last year.
Yangzijiang Pharmaceutical Group's Suhuang cough capsules have the effect of relieving the lungs and suppressing cough and throat, and are used for cough and itchy throat caused by lung and lung qi deficiency, and are national medical insurance class B and national basic
medicines.
In 2021 and the first half of 2022, the terminal sales scale of Suhuang cough capsules in public hospitals in key cities increased by 24.
99% and 22.
26%
year-on-year, respectively.
Peking University Weixin's Xuezhikang capsules are proprietary Chinese medicine extracted from red yeast rice and indicated for hypercholesterolemia
.
The product has been verified by comprehensive evidence-based medical clinical research, and the lipid-lowering effect has been internationally recognized
.
In January 2019, AstraZeneca signed an agreement with Luye Pharmaceutical to obtain the exclusive promotion right of Xuezhikang capsules in Chinese mainland, which is also the first time for a large multinational pharmaceutical company to promote proprietary Chinese medicine products
in China.
With the help of AstraZeneca, the market of blood lipid capsules has continued to expand in recent years, with growth rates of 32.
71%, 22.
62% and 16.
52%
from 2020 to 2022H1 respectively.
